COPD Symposia
In this section
GOLD 2023 – Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD
This symposium explores the heterogeneous clinical presentation of chronic obstructive pulmonary disease (COPD), addressing variations in severity, symptoms, and comorbidities.
Learning objectives
- Understand the heterogeneous clinical presentation of COPD (eg, severity, level of control, symptoms, multimorbidities)
- Review the role of underlying inflammation in COPD pathology and its link to clinical features
- Review the role of biomarker assessments and endotyping in COPD
Meet the expert
Igor Barjaktarevic, MD, PhD
Assistant Professor of Medicine, Medical Director of COPD Program – David Geffen School of Medicine at University of California-Los Angeles (UCLA)
As Assistant Professor of Medicine and Medical Director of the COPD Program at the David Geffen School of Medicine at UCLA, Dr. Barjaktarevic leads the clinical and research projects in COPD and alpha-1 antitrypsin deficiency syndrome.
With a fairly extensive background in the field of pulmonary immunology where Dr. Barjaktarevic obtained a PhD in 2016 in collaborative project between University of Belgrade and Weill Cornell in New York, his research experience expands from basic science and experiments on laboratory animals to complete conduction of clinical or translational studies.
Disclosures:
Dr. Barjaktarevic has received funding from Alpha-1 Foundation, COPD Foundation, Johnny Carson Foundation, and NIH National Heart, Lung, and Blood Institute; grants from Aerogen, GE HealthCare, Takeda, Theravance, and Viatris; and has consulting relationships with AstraZeneca, Grifols, Inhibrx, Regeneron, Sanofi, Takeda, and Verona Pharma.
ERS 2023 – The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology
This symposium explores chronic obstructive pulmonary disease (COPD)'s clinical presentation through disease pathology, emphasizing its diverse inflammatory pathways.
Learning objectives
- Describe the clinical consequences of COPD through an understanding of pathological changes
- Understand the spectrum of inflammatory pathways and the role of type 2 inflammation in COPD pathophysiology
ERS 2023 – Contextualizing Clinical Consequences of COPD Through Disease Pathology
Prof. Klaus Rabe shares an overview of the underlying pathology of COPD and the clinical consequences of pathologic changes.
ERS 2023 – Heterogeneity of Inflammatory Pathways in COPD
Dr. Stephanie Christenson shares an overview of inflammatory pathways underlying COPD, including type 2 inflammation.
Meet the experts
Stephanie Christenson, MD, MAS
Associate Professor at the University of California, San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Dr. Christenson earned her medical degree from the Medical College of Wisconsin. She completed a residency in internal medicine at Boston University School of Medicine. At UCSF, she completed a fellowship in pulmonary and critical care medicine and a master of advanced study degree in clinical research. She currently is a member of the American Thoracic Society.
Dr. Christenson cares for patients in the intensive care unit as well as patients with lung disease in the clinic.
Disclosures:
Dr. Christenson has acted as a consultant/writer for AstraZeneca, GlaxoSmithKline, Glenmark, Regeneron, Sanofi, and UpToDate.
Klaus Rabe, MD, PHD, FERS
Professor of Pulmonary Medicine – University of Kiel; Director of the Department of Pneumology – LungenClinic Grosshansdorf, Kiel, Germany
Prof. Rabe is a Fellow and Past President of the European Respiratory Society and currently serves as Vice Chairman of the German Center for Lung Research. He is the Past President of the German Chest Society, and a member of the British Pharmacological Society and the American Thoracic Society. He has served on committees for the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease.
Prof. Rabe serves on the editorial board of several journals including the American Journal of Respiratory and Critical Care Medicine and is past Chief Editor of the European Respiratory Journal. He has received several distinctions, including the Balzan award in 2019.
Prof. Rabe has been active in various fields of respiratory medicine worldwide. His current scientific interests are related to large clinical trials in COPD and asthma, the mechanisms of airway inflammation, and early determinants of lung health. Prof. Rabe has been involved in many major COPD trials, including the pivotal studies on phosphodiesterase inhibitors and biologics for asthma and COPD.
Disclosures:
Prof. Rabe has received grants/research support from the German Federal Ministry for Research and Technology (BMFT) and honoraria or consultation fees from AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim, Chiesi USA, GlaxoSmithKline, Menarini, Novartis, Regeneron, Sanofi, and Verona Pharma. Other support/potential conflict of interest: Director of the Airway Research Center North (ARCN) within the Deutsche Zentrum für Lungenforschung (DZL).
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority in collaboration with Sanofi and Regeneron, with content provided by Sanofi and Regeneron. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-US-2405120 V1.0 – P Exp Date: 06/11/2026.
Sanofi and Regeneron are committed to providing resources to advance knowledge in areas of unmet medical need among patients with inflammatory and immunologic diseases.